Jan 2016

Jan 2016 EdiGene Corporation founded

Apr 2016

Established fully owned US subsidiary, EdiGENE Inc. (Now Modalis Therapeutics Inc.)

Apr 2017

Initial research collaboration formed with Astellas Pharma Inc.

Sep 2017

Obtained license on engineered Cas9 technology from University of Tokyo

Feb 2019

Established a license agreement on a genetic disorder with Astellas Pharma Inc.

Mar 2019

US subsidiary relocated to the new facility

Aug 2019

EdiGene renamed to Modalis Therapeutics

Sep 2019

Established 2nd license agreement for additional genetic disorder with Astellas Pharma Inc.

Nov 2019

Collaboration agreement with Eisai Co., Ltd.

Apr 2020

Modalis Obtains Access to Foundational CRISPR IP

Aug 2020

Listing on Mothers, Tokyo Stock Exchange (Ticker symbol: 4883)

Oct 2021

US subsidiary relocated to the new facility